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Over the past 2 years there has been a radical change in standard clinical practice with respect to vitamin D.
As a result of a growing body of knowledgeable physicians are assessing the vitamin D nutritional status of
their patients and prescribing aggressive repletion regimens of a vitamin D supplement. The present paper
summarizes some basic information about this essential nutrient and reviews some of the more recent data
implicating vitamin D deficiency in disease etiology with an emphasis on cardiovascular disease and cancer.
Finally a rational approach to the dosing of vitamin D in different patient populations is provided.
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O
ver the past 5 years there has been a marked
increase in the number of high-dose vitamin D
prescriptions in the United States. A spike in
prescriptions for a particular drug is normally observed
following the publication of a seminal clinical study
whose compelling results command attention and dictate
changes in standard clinical practice. This review explores
the data behind this prescribing trend.
Vitamin D has a long and interesting history that is
closely linked to that of the childhood bone disease
rickets. Although the existence of vitamin D had been
suspected since the mid-17th century, it was not actually
discovered until 1920 and its chemical structure was not
elucidated until 1932 (13).
In the decades that followed its discovery, an over-
whelming body of clinical and laboratory evidence estab-
lisheditscriticalroleinthemaintenanceofcalciumbalance
and skeletal health. Thus, vitamin D is associated first and
foremost with these functions. However, a quick survey of
thecurrent literature reveals that vitamin D is at thecenter
ofanendocrine system that regulatescellular proliferation
and differentiation in addition to a wide range of other
cellular processes, extending the role of vitamin D beyond
the skeleton to include the immune, cardiovascular, and
neuroendocrinesystems.Suchasurveywouldalsoindicate
that vitamin D deficiency aswell as genetic variation in its
receptors may play a significant role in the etiology of a
variety of chronic disorders including mycobacterial
infections, diabetes, cardiovascular diseases, cancer (e.g.
colorectal), and autoimmune diseases such as systemic
lupus erythematosus (SLE), multiple sclerosis, rheumatic
arthritis, and psoriasis. Vitamin D is now a highly active
field of research. Over 2,300 papers on the subject were
published in the first 9 months of 2010.
Following a summary of a few essential facts about
vitamin D, the review will focus on its role in disease
etiology, and the experts’ opinions concerning the
optimal vitamin D levels and daily doses for different
patient populations.
Physiology of vitamin D
Vitamin D belongs to the quartet of fat soluble vitamins
(A, D, E, and K). This accounts for its distribution
primarily in adipose tissue and its very slow turnover rate.
Structurally, it is a secosteroid with a ring structure
similar to cholesterol except for abroken CC bond in the
B ring (Fig. 1a and b).
There are two main forms of vitamin D: the first is
vitamin D2, which is also referred to as ergocalciferol or
calciferol.Itisproducedbytheirradiationofyeastorplant
ergosterol. The second and more important is vitamin D3
(cholecalciferol), which is derived from the photoconver-
sion of 7-hydrocholesterol in the skin upon exposure to
sunlight or artificial ultraviolet radiation (wave length
range 285315 nm, known as UVB). Significant amounts
of vitamin D3 can also be obtained from fish liver oil and
oily fish in general and very small amounts from other
animal products. Supplemented milk sold in the United
States contains approximately 100 international units
(IUs) per cup. Vitamin D3 is produced commercially
starting with lanolin (wool fat) as the raw material.
Of course both D2 and D3 are available in pill form.
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over-the-counter (OTC) products in tablet or capsule
form (2005,000 IUs each) or oral liquid form. Vitamin
D2 is available by prescription in the form of capsules
containing 50,000 IUs each. Vitamin D2 is biologically
weaker than D3, possessing only about 30% of vitamin D3
activity.
In the body, the two forms (D2 and D3) follow similar
metabolic pathways. However, our focus in this review will
be primarily on D3 since it constitutes the predominant
input and the naturally occurring form in humans. In
the liver, cholecalciferol (D3) is hydroxylated in position
25 to form 25-hydroxy-cholecalciferol [25(OH)D3] (also
called calcidiol, Fig. 3). This reaction is catalyzed by
25-hyroxylases that are cytochrome P450 enzymes located
in the endoplasmic reticulum such as the microsomal
CYP2R1 and the mitochondria CYP27A1. Calcidiol
[25(OH)D3] represents the storage form and the major
circulatingmetaboliteofvitaminD3.Itslevelintheplasma
is used clinically to assess apatient’s vitamin D nutritional
status. In the circulation, vitamin D and its various
metabolites travel aboard a specific carrier protein known
as a vitamin D-binding protein (DBP). At physiological
concentrations,vitaminD2,vitaminD3,andcalcidiolhave
virtually no intrinsic biological activity. In the kidney, a
secondhydroxylgroupisaddedtothecalcidiolmoleculein
position 1 to form 1a,25-dihydroxycholecalciferol
[1,25(OH)2D3], often referred to as calcitriol. In the
kidney, this reaction is catalyzed by 1a hydroxylase, a
cytochrome P450 enzyme (CYP27B1). Calcitriol is the
active, hormonal form of vitamin D3 whose serum level
normally ranges between 15 and 75 pg/mL. Calcitriol is
available by prescription in oral and injectable forms for
patients with advanced kidney disease. Some calcidiol is
hydroxylated in position 24 (instead of position 1) to form
24,25-dihydroxy-cholecalciferol [24,25(OH)2D3], which is
also biologically active (Fig. 2). Other products include
25,26(OH)2D3 and 25(OH)D3 23-26 lactone.
Mutation of the gene coding for the 1a hydroxylase
(CYP27B1) results in the rare disease of vitamin D
pseudodeficiency, which is characterized by an undetect-
able level of circulating calcitriol, hypocalcemia, hyper-
parathyroidism, and rickets (4). Production of calcitriol
anditscirculatingleveldependonseveralfactors,themost
important of which is the activity of 1a-hydroxylase
(CYP27B1) in the proximal tubule cells of the kidney.
The activity of this enzyme is enhanced by low calcitriol
levels, high parathyroid hormone (PTH), hypocalcemia,
and hyperphosphatemia. However, in addition to the
1a-hydroxylase activity, a key determinant of calcitriol
production rate is the circulating concentration of its
immediate precursor, calcidiol [25(OH)D3], which
depends on vitamin D3 inputs (skin exposure to UVB
radiation and/or oral intake of D3). Calcitriol production
is inhibited by the fibroblast growth factor 23 (FGF23)
in association with a-Klotho as a cofactor; a-Klotho
is a protein that appears to be a key player in a
complex regulatory system of calcium and phosphate
homeostasis (5).
Both calcidiol and calcitriol are ultimately inactivated
through an oxidative pathway involving CYP24A1,
which has been shown in experimental animals to play
a critical role in the prevention of vitamin D toxicity (6).
The end product of calcitriol oxidation (via CYP24A1) is
calcitroic acid that is eliminated in the urine.
Fig. 1. (a) Basic chemical structure of a steroid. When UVB rays strike 7-hydrocholesterol in the epidermis the C9C10 bond in
the B ring breaks forming an intermediate compound called pre-D3 that isomerizes to D3. (b) The structures of calciferol (D2)
and cholecalciferol (D3). The structural differences between the two compounds are limited to the side chain; D2 has one
additional methyl group and a double bond.
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active metabolite calcitriol fits the definition of a
hormone; it is produced by a discrete organ (a gland,
the kidney in this case), travels through the circulation to
reach specific target tissues, and interacts with specific
receptors in the target cells to trigger predictable biolo-
gical responses. Most of the known actions of calcitriol
are mediated via a nuclear transcription factor known
as the vitamin D receptor (VDR). In the cell nucleus
calcitriol binds to VDR and causes it to bind to the
retinoic acid x-receptor (RXR). The calcitriolVDR
RXR complex binds to certain DNA segments known
as the vitamin D response elements (VDREs) to initiate
the regulation of specific genes. Calcitriol is involved in
the regulation of more than 200 genes, including those
controlling insulin synthesis, renal renin production,
the proliferation and growth of cardiac and vascular
muscle cells, the release of cytokines by the T cells, and
the production in macrophages of the antimicrobial
peptide cathelicidin.
There are significant individual and ethnic variations
in the gene coding for VDR. These genetic variations
(polymorphisms) that usually involve a single nucleotide
are thought to be largely responsible for the variation in
individual response to vitamin D and may be a significant
determinant of the risk for different diseases (79).
In addition to the nuclear VDR, another kind of
vitaminDreceptorexiststhatisassociatedwiththeplasma
membrane rather than the nucleus. This membrane-
associated receptor is thought to mediate rapid, non-
genomic cellular responses to calcitriol such as insulin
secretion, the opening of voltage-gated ion channels in
osteoclasts, and the rapid translocation of calcium ions
across the wall of the small intestine (1012).
Fig. 2. Hydroxylation of vitamin D3.
Fig. 3. Systemic and local formation of calcitriol.
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deficiency is the primary cause of the bone disease known
as rickets in children and osteomalacia in adults. In the
1940s it became mandatory in the United States to fortify
milk with vitamin D3, which resulted in a dramatic decline
in the incidence of rickets. Consequently, most of the early
research focused on the role of vitamin D in regulating
calcium balance, skeletal development, and maintenance
of bone health. The small intestine, kidneys, parathyroids,
and bone have been identified as the effector organs
involved in the calcitriol endocrine regulatory system. It is
in these target tissues that the presence of the nuclear
vitamin D receptor (VDR) was first established. However,
over the past 25 years VDR has also been found in over
30 other cell types including the brain, skeletal muscle,
heart, smooth muscle, skin, beta cells of the pancreas, and
cells of the immune system (macrophages, dendritic cells,
and B & T lymphocytes). Researchers have also revealed
the extrarenal presence of 1a-hydroxylase (CYP27B1)
in many tissues (colon, prostate, dendritic cells, skin,
etc.) where locally produced calcitriol appears to serve
localized (paracrine) functions (Fig. 3) and where its local
production does not contribute to the circulating pool of
calcitriol except in the case of granulomatous diseases
such as sarcoidosis probably due to the absence in
macrophages of CYP24A1, which is responsible for the
oxidative deactivation of calcitriol (4).
Vitamin D and the immune system
Despite the recent expansion in vitamin D research, an
immense gap remains in our knowledge of its multiple
functions in the variety of cell types where the presence
of vitamin D receptors and paracrine production of
calcitriol have been established. However, it is now
generally accepted that a strong connection between
vitamin D and the immune system exists as suggested
by several key findings: (a) the presence of VDR in
activated human immune cells, (b) the ability of these
cells to produce calcitriol, and (c) the ability of calcitriol
to inhibit the proliferation of T cells. In addition, it has
become increasingly evident in recent years that calcitriol
plays a significant role in modulating the function of the
immune system. Furthermore, many epidemiological
studies strongly suggest that vitamin D deficiency and
certain VDR polymorphisms may be linked to immune
system related diseases such as multiple sclerosis, SLE,
DM type I, alopecia (areata or universalis), and psoriasis
(1318).
Upon penetrating the body, the microbe sheds its
pathogen-associated molecular patterns (PAMPs), which
arequicklyrecognizedby thetoll-likereceptors(TLRs) on
the surface of the immune cells. This recognition triggers a
complex cascade of events inside the host immune cell,
which leads to the initiation of the innate immune system
response. This includes the release of cytokines, enhanced
expression of antimicrobial peptides (natural antibiotics)
such as cathelicidin, and a surge in the production of
reactive oxygen species. Several studies have now demon-
stratedthatinjuryortheadditionofmicrobiallipopeptides
enhances the expression of CYP27B1 (1a-25OH-D3
hydroxylase) and the paracrine production of calcitriol.
Also, the expression of cathelicidin in both myeloid and
epithelial cells is induced by calcitriol. These observations
suggest that this hormone plays a significant role in the
host immune response (1924). Further, in the absence of
adequate levels of 25(OH)D3 (calcidiol), the paracrine
production of calcitriol and the expression of cathelicidin
are both markedly reduced.
A recent study by Krutzik et al. has clearly demon-
strated the absolute need for IL-15, which is produced by
the innate immune cells upon the activation of TLR2/1;
IL-15 is essential for the induction of CYP27B1 and the
conversion of calcidiol to calcitriol, leading to VDR
activation and the expression of cathelicidin (25). In
addition, the antimicrobial activity of cathelicidin against
intracellular pathogens such as mycobacterium tubercu-
losis has been demonstrated. This may explain the
salubrious effect of sun exposure on tuberculosis patients.
The overall effect of calcitriol on the adaptive immune
system is suppressive; it suppresses antibody production
by inhibiting the differentiation of B cells into the
immunoglobulin producing plasma cells. With respect
to the T cells, the actions of calcitriol are more complex.
By affecting the secretion of various cytokines, calcitriol
promotes the functions of Th2 and Treg (previously
known as suppressor T cells) and inhibits the develop-
ment and function of Th1 and Th17 (25).
These effects may form the basis for the connection
between vitamin D deficiency and autoimmune diseases.
The inhibition of Th1 by calcitriol leads to decreased
production of both INF-g and IL-2; this in turn results in
the suppression of macrophage activation and antigen




Epidemiology of vitamin D deficiency
Vitamin D deficiency is now recognized as a pandemic
particularly in the northern hemisphere where winters
are severe and sun exposure is minimal. Vitamin D is
lipophilic and distributes preferentially into the adipose
tissue with a half-life of approximately 2 months. As
mentioned above, the biomarkerof vitamin D status is the
level of circulating calcidiol [25(OH)D], which due to its
lipophilic nature distributes into the adipose tissue and
represents the storage form of vitamin D with a half-life of
15 days. Vitamin D deficiency is defined as a calcidiol
levelB20 ng/mL, insufficiency as a level of 2129 ng/mL,
andsufficiencyasa level 30ng/mL (1ng/mL2.5 nmol/
Nasr Anaizi
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are gradually shifting upward as vitamin D deficiency
is increasingly being implicated in the etiology of an
expanding list of diseases. Obvious vitamin D toxicity
manifested as hypercalcemia and ectopic calcification
does not occur until the calcidiol level is well above
150 ng/mL. However, the long-term safety of sustained
high levels ( 50 ng/mL) is yet to be determined since the
trend of prescribing vitamin D mega-doses has become
widespread only recently. Therefore any benefit of vitamin
D intake has to be balanced against the risk of known
short-term and potential long-term toxicities (27, 28).
The Third National Health and Nutrition Examination
Survey (NHANES III) has revealed that a large segment
of the American population have low vitamin D levels, a
fact that has been confirmed in many other studies. The
phenomenon of vitamin D deficiency has also been found
in many other parts of the world including North Africa
and the Middle East where social customs dictate minimal
skin exposure. The reasons for vitamin deficiency are
multiple and include indoor life style, high latitude,
dark skin, insufficient skin area exposed to UVB,
obesity (expanded volume of distribution), aging (reduced
capacity for photosynthesis), severe liver disease, and
chronic kidney disease (CKD).
In addition to bone diseases in both children and
adults, vitamin D deficiency has been linked to a wide
variety of chronic conditions including diabetes mellitus
type II, hypertension, colorectal cancer, infectious dis-
eases, and autoimmune diseases such as SLE and diabetes
mellitus type I. However, in most of these conditions a
causal relationship and the pathophysiological mechan-
isms involved have not yet been established.
Vitamin D and cardiovascular disease (CVD)
Calcitriol plays a significant role in the regulation of many
genes including those involved in the regulation of renal
renin production and the proliferation and growth of
cardiac and vascular muscle cells. Also, calcitriol has an
anti-inflammatoryeffectmanifestedinthedownregulation
of C-reactive protein and other proinflammatory markers.
Thus it is not surprising that vitamin D deficiency has
a negative impact on cardiovascular health. Several
observationalstudiespointtoastrongassociationbetween
vitamin D deficiency and cardiovascular mortality adding
a potential novel CVD risk factor. In a retrospective study
focusing on racial differences between black and white
Americans, Fiscella and colleagues evaluated data from
nearly 15,000 participants in the NHANES III (1988
1994) and cause-specific mortality through 2001 using
the National Death Index. Black participants with
calcidiol levels in the lowest quartile (mean13.9 ng/L
34.8 nmol/L) had a 40% greater risk of death due to
coronary heart disease, heart failure, or stroke compared
with those whose levels were in the three higher quartiles
(means: 21.6, 28.4, and 41.6 ng/mL). With respect to race,
the study found that blacks have a nearly 40% greater risk
of CVD related mortality than whites, but this difference
was reduced to 14% when the two groups were matched
withrespecttothecalcidiollevel(29).Severalotherstudies
havealsoshownvitaminDdeficiencytobeassociatedwith
a higher risk for metabolic syndrome, hypertension, and
adverse cardiovascular events (2931). Revved up renin
angiotensinaldosterone system, insulin resistance, and
secondary hyperthyroidism arethought to mediate at least
some of the cardiovascular effects of vitamin D deficiency.
In 2008, Lee and colleagues reviewed this topic in greater
detailfortheJournaloftheAmericanCollegeofCardiology
(32).
Vitamin D and cancer
One of the earliest hints of a possible association between
vitamin D deficiency and cancer is the observation that
both vitamin D deficiency and the incidence of certain
cancers vary by latitude. This is thought to be related to
the northsouth sunshine gradient and is sometimes
referred to as the geographic or ecological factor.
In an epidemiological study involving 111 countries, a
strong positive association between latitude and the
incidence rates of lung cancer was found. At the same
time therewas an inverse relationship betweenlung cancer
rates and the effective exposure to UVB rays. Having
accounted for other factors such as cigarette smoking, the
authors concluded that low levels of UVB irradiance are
independently associated with higher incidence rates of
lung cancer (32). Retrospective analysis of more than
60 observational studies in the United States suggests that
inadequate vitamin D levels may be associated with a
higher incidence of cancer in general (3337).
In a follow-up study lasting 18 years and involving
nearly 15,000 men who participated in the United States
Physicians’ Health Study it was concluded that men
whose calcidiol levels were below the median concentra-
tion of 25 ng/mL in the winter and 32 ng/mL in the
summer had a significantly greater risk of prostate cancer
than those whose levels were above the median (odd
ratio2.1 with 95% confidence interval 1.23.4). When
the low calcidiol level was associated with the less
functional VDR FokI ff genotype (as opposed to FokI
FF) the risk was greater and the cancer more aggressive
(34). There have also been numerous other retrospective
analysis and nested studies suggesting a potential for
cancer prevention by maintaining adequate circulating
vitamin D levels. Data from the Women’s Health
Initiative point to the possibility that chronic vitamin D
deficiency [calcidiol levelsB23 ng/L (58 nmol/L)] may be
associated with increased incidence of malignancy (35).
In a prospective study involving 1,179 patients with an
average baseline calcidiol level of 28 ng/mL, Lappe et al.
compared the effects of daily intake of calcium (about
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placebo over a period of 4 years. Supplementation
resulted in raising the serum calcidiol level above 38 ng/
mL. After excluding patients who were diagnosed with
tumors within the first year of study, the Ca plus D3
group had a significantly lower incidence of malignancies
than the other two groups (38).
This wealth of information prompted the International
Agency for Research on Cancer (IARC) to charge a
number of expert panels with the task of conducting in-
depth reviews of available data related to Vitamin D and
cancer. The groups conducted various types of studies
including meta-analyses, prospective, and nested and
published their initial reports in 2008. The Cohort
Consortium Vitamin D Pooling Project (VDPP) pooled
data from patient populations (cohorts) with a consider-
able degree of diversity in terms of race and geography
and spanning a period ofover 30 years. One conclusion of
these studies is that adequate vitamin D (calcidiol) levels
provide significant reduction in the risk for colorectal
cancer. Data from prospective studies demonstrated a
statistically significant decrease in the risk of colorectal
cancer per 1 ng/mL increase in serum calcidiol level
(RR0.984, 95% CI: 0.976, 0.991). However, for both
breast and prostate cancers, meta-analyses of pooled data
were inconclusive (37). Meta-analysis of the prospective
breast cancer studies yielded mixed results and the
observed risk reductions were not statistically significant
(RR0.994, 95% CI: 0.964, 1.024). For prostate cancer,
solid evidence is still lacking for an association with the
vitamin D nutritional status.
The picture for pancreatic cancer is even more compli-
cated. Laboratory studies suggest that vitamin D plays a
significant role in both function and dysfunction of
the pancreas. Pancreatic cells possess VDR and express
CYP27B1(calcidiol 1a-hydroxylase).Calcitriolappearsto
be involved in the regulation of insulin synthesis, release,
andfunction.VitaminDmetabolitesandsyntheticanalogs
inhibit pancreatic cell line growth and promote apoptosis
of pancreatic cancer cells in vitro. Furthermore, over
the past 7 years, several ecological studies have suggested
an inverse relationship between UVB exposure (and
presumably vitamin D status) and the incidence of
pancreatic cancer (3842). In light of this background the
results of recent studies were totally unexpected.
A nested study of Finnish male smokers (part of the
a-tocopherol, b-carotene, ATBC Study) revealed that
highercalcidiollevelsareassociatedwithanearlythreefold
rise in the incidence of pancreatic cancer (43). Also, a
prospective study suggests that individuals with consis-
tently high calcidiol levels are at a significantly higher risk
forpancreaticcancerrelativetothosewithadequateorlow
levels. However, there was no concentration-response
relationship (44).
Further, a pooled nested case-control study of patients
from eight cohorts within the Cohort Consortium VDPP
of Rarer Cancers evaluated whether prediagnostic serum
calcidiol levels were associated with the development of
pancreatic cancer. During a median follow-up period
of 6.5 years, 952 cases of pancreatic adenocarcinoma
cases occurred among participants. The control group
consisted of 1,333 participants matched within each
cohort for age, sex, race, and so on. Overall, after
adjusting for other risk factors (smoking, obesity, and
diabetes), a circulating calcidiol level greater than 40 ng/
mL (100 nmol/L) was associated with a statistically
significant twofold increase in the risk for pancreatic
cancer (45).
Daily vitamin D intake
At present, there are no established guidelines for dosing
vitamin D in the various patient populations (infants,
children, adolescents, young adults, seniors, pregnant,
lactating, or menopausal women) that take into account
clinical information acquired in recent years as well as the
factors that determine effective UVB exposure (latitude,
season, clothing and skin area exposure, skin pigmenta-
tion)andotherriskfactorsforvitaminDdeficiencysuchas
obesity,oldage,smoking,liverandchronickidneydisease,
and certain drugs (steroids, barbiturates, and anti-
convulsants).However,anevaluationofrecentlypublished
literature suggests that the currently recommended daily
allowances are probably too low and that higher doses are
required to achieve the best outcomes at least in terms of
bone health and colorectal cancer. Until revised, optimal
vitamin D intakes are defined and due to the multiplicity
andcomplexityofthefactorsthatdeterminenetvitaminD
input, it appears reasonable based on available datato aim
for a serum calcidiol level between 30 and 40 ng/mL (75
100nmol/L)andmodifythedailyvitaminDsupplementas
necessarytoachievethislevel.Oncereached,thislevelmay
be maintained in adults with a daily vitamin D3 dose of
1,0002,000 IUs (46).
Adolescents (1017 years) and seniors (]65 years) may
require higher doses (]2,000 IUs/day). For children in the
first year of life, there are data suggesting significant
benefits from a daily vitamin D3 dose of 2,000 IUs.
A Finnish study of over 10,000 children found that a daily
dose of 2,000 IUs in the first 12 months of life reduced the
risk of type I diabetes by 78% in the following 31 years of
life (4749).
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